Zim Laboratories LtdQ3 FY25
Zim Laboratories Ltd Q3 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹121P/E: 75.2Market Cap: ₹526 CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 2
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3No information is provided regarding the same in the latest conference call.
Margin guidance
Category 2No information is provided regarding the same in the latest conference call.
3 more insights locked — sign up free to unlock
Fundraise plans
NoNo information is provided regarding the same in the latest conference call.
Order book
No information is provided regarding the same in the latest conference call.
Capex plans
YesNo information is provided regarding the same in the latest conference call.
How does Zim Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Zim Laboratories Ltd
Rev 3Mar 2
See full Pharmaceuticals & Biotechnology sector rankings